622 results on '"Wirth, Lori J."'
Search Results
2. Accelerated approvals hit the target in precision oncology
3. Does Current Training in Radiation Oncology Prepare Radiation Oncologists to Optimally Manage Patients With Head and Neck Cancer?
4. Predicting response to immune checkpoint blockade in recurrent/metastatic head and neck squamous cell carcinoma using personalized circulating tumor DNA.
5. Patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) with BRAF V600E and/or K601E mutation status: A real-world view of effectiveness of lenvatinib monotherapy.
6. Impact of tertiary lymphoid structures in response to immune checkpoint blockade in patients with head and neck squamous cell carcinoma.
7. Multi-feature next-generation liquid biopsy for diagnosis and prognosis in HPV-associated head and neck cancer.
8. Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma
9. Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
10. FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy.
11. Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.
12. Recovery of Recurrent Laryngeal Nerve Function With Neoadjuvant Treatment: Neural Characterization.
13. Management of Patients with NTRK Fusion-Positive Thyroid Cancer.
14. Efficacy and Safety of NTRK Inhibitors in Patients With NTRK Fusion-Positive Lung and Thyroid Cancers.
15. Screening and Validation of Molecular Targeted Radiosensitizers
16. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
17. A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma
18. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
19. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization
20. Vemurafenib in patients with BRAF V600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
21. Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer
22. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
23. Return of Vocal Fold Motion and Surgical Preservation of Invaded Recurrent Laryngeal Nerves After the Use of Neoadjuvant Therapy in Patients Presenting with Advanced Thyroid Cancer and Vocal Fold Paralysis: The Lazarus Effect
24. Q&A: Barriers to Testing for NTRK Fusions in Metastatic Lung and Thyroid Cancer.
25. Contributors
26. Medical Treatment Horizons for Metastatic Differentiated and Medullary Thyroid Cancer
27. Anaplastic Thyroid Carcinoma, Version 2.2015.
28. Thyroid carcinoma, version 2.2014.
29. Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update.
30. Figure 1 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
31. Figure 2 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
32. Supplementary_Table5 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
33. Figure 7 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
34. Figure 6 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
35. Supplementary Figures S1-S7 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
36. Data from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
37. Figure 3 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
38. Figure 5 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
39. Figure 4 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
40. Amygdalar activity measured using FDG-PET/CT at head and neck cancer staging independently predicts survival
41. Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas
42. Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
43. Cabozantinib in Progressive Medullary Thyroid Cancer
44. The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors
45. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.
46. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model
47. A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer.
48. Medullary Thyroid Cancer: Updates and Challenges
49. Related Article from Chemoprevention of Squamous Cell Carcinoma of the Head and Neck: No Time to Lose Momentum
50. Supplementary Materials 3 from Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.